AIM-quoted refugee from the Full List, Amberley Group, the former speciality mineral and chemical outfit now a shell company run by French entrepreneur Guy Naggar, lost £68,000 in the six months to October and is continuing to 'search for opportunities to create significant shareholder value in the long term'. Robert Tyerman reports.
Amberley, which raised £1 million at 10p plus warrants in August, says its net asset value at the end of October was £2.45 million, or 6.95p a share, including £2.3 million cash. In late October, the company bought contracts for difference over ten million shares in fully listed fibres, umbrellas and wall coverings group Chapelthorpe at an average price of 18.9p a share, against today's 20p.
Naggar says Amberley has looked at 'a number of potential investments, in both the public and private arena' and promises that 'shareholders will be kept informed of any major developments'. Positive news would be welcome indeed for investors who have seen the shares halve to 12p since 2000.
The most comprehensive review of AIM directors' pay available, and this year includes a record sample of 1000+ AIM-quoted companies. The full report is available to order for £385 + VAT. Click here for more info
Latest small-cap and growth company news
Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.
Forbidden Technologies (AIM: FBT) has been around a long time but has failed to generate much in the way of revenues, despite having a product that sounds like it should be a winner. There were board changes last year and new CEO Aziz Musa is shifting resources towards selling and away from technological development. This has to be the right strategy and we should find out if it’s working as this year unfolds.
Tyratech (AIM: TYRU) offers a compelling product proposition. Controlling bugs and parasites using conventional pesticides is both harmful to the environment and ineffective. Over the years insects have built up resistance to many of the chemicals used to kill them. So Tyratech’s natural products are not only safer but also a lot more effective than the competition.
Results from medical device manufacturer Angle (AIM: AGL) showed its innovative Parsortix system to be nicely on track. The first commercial sales for research use have just been made and three leading cancer centres are moving forward with trials that will support its clinical use in the diagnosis of ovarian cancer.
The 12th annual Grant Thornton Quoted Company Awards took place this week at the Natural History Museum in London. This prestigious event is organised by Growth Company Investor and is a celebration of the success and achievements of the UK’s smaller company sector. We published the shortlisted nominees for each award category earlier in January; so read on to see who the winners were...
In the middle of 2014 Plexus (AIM: POS) was riding high with a share price of 320p giving the company a market value of £270 million. Today’s profit warning has seen the shares slump 40 per cent to just 73p, valuing Plexus at a mere £65 million. As an engineering company selling mainly into the oil industry, we shouldn’t be too surprised by downgrades. But the severity is startling.
Malaysian big data software specialist Fusionex (AIM: FXI) has released an upbeat results statement for the year to September. As well as beating historic forecasts, the new financial year is said to have started “on a very strong note… the outlook for 2016 and beyond is very positive”. Sounds fantastic! Yet by this afternoon the shares had collapsed by 35 per cent.